Silence Therapeutics PLC
SLN5.910USD
-0.260-4.21%
Horário de mercado （ET）Cotações atrasadas em 15 min
837.39MValor de mercado
PerdaP/L TTM
Mais detalhes de Silence Therapeutics PLC Empresa
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Informações da empresa
Código da empresaSLN
Nome da EmpresaSilence Therapeutics PLC
Data de listagemJan 05, 2010
CEOMr. Craig A. Tooman
Número de funcionários116
Tipo de títulosDepository Receipt
Fim do ano fiscalJan 05
Endereço72 Hammersmith Road
CidadeLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalW14 8TH
Telefone442034576900
Sitehttps://www.silence-therapeutics.com/
Código da empresaSLN
Data de listagemJan 05, 2010
CEOMr. Craig A. Tooman
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
Investidores
Investidores
Proporção
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
5.91%
Redmile Group, LLC
4.69%
Morgan Stanley & Co. LLC
4.01%
Other
54.59%
Tipos de investidores
Investidores
Proporção
Individual Investor
24.38%
Investment Advisor
18.47%
Investment Advisor/Hedge Fund
10.53%
Hedge Fund
7.10%
Research Firm
5.08%
Venture Capital
3.35%
Private Equity
2.43%
Other
28.65%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
130
33.69M
71.34%
-14.09M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
2023Q2
54
31.78M
89.08%
+2.79M
2023Q1
52
31.17M
88.54%
+2.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.79M
5.91%
-41.94K
-1.48%
Mar 31, 2025
Redmile Group, LLC
2.21M
4.69%
-184.37K
-7.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.90M
4.01%
+333.48K
+21.34%
Mar 31, 2025
Lombard Odier Asset Management (USA) Corp.
1.85M
3.92%
-6.29K
-0.34%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.15M
2.43%
--
--
Mar 31, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
-7.25K
-0.69%
Mar 31, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.01%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.93%
ProShares Ultra Nasdaq Biotechnology
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
iShares Biotechnology ETF
Proporção0.01%
SPDR S&P International Small Cap ETF
Proporção0.01%
ActivePassive International Equity ETF
Proporção0%
Tema Heart & Health ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
